Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications

Critical Care Medicine

Volumn 28, Issue 7, 2000, Pages 2209-2216

  Mesters, Rolf M ^a   Helterbrand, Jeff ^b   Yan, S Betty ^b   Utterback, Barbara G ^b   Chao, Y Bernice ^b   Fernandez, Jose A ^c   Griffin, John H ^c   Hartman, Daniel L ^d  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d PFIZER INC   (United States)

Author keywords

Activated protein C; D dimer; DIC; Leukemia; Protein C; Sepsis; Septic shock; Severe sepsis

Indexed keywords

ACTIVATED PROTEIN C; CYTOSTATIC AGENT; D DIMER; PROTEIN C;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FATALITY; FEVER; HUMAN; LEUKEMIA; NEUTROPENIA; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK;

EID: 0033860427     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200007000-00005     Document Type: Article

References (73)

1. 1. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
2. 2. Glauser MP, Zanetti C, Baumgartner JD, et al: Septic shock: Pathogenesis. Lancet 1991; 338:732-736
3. 3. Bone RC: Modulators of coagulation: A critical appraisal of their role in sepsis. Arch Intern Med 1992; 152:1381-1389
4. 4. Levi M, van der Poll T, ten Cate H, et al: The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 1997; 27:3-9
5. 5. Carrico CJ, Meakins JL, Marshall JC, et al: Multiple organ failure syndrome. Arch Surg 1986; 121:196-208
6. 6. Fourrier F, Chopin C, Goudemand J, et al: Septic shock, multiple organ failure, and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-823
7. 7. Asakura H, Jokaji H, Saito M, et al: Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers. Blood Coagul Fibrinolysis 1994; 5:829-832
8. 8. Esmon NL, Owen WG, Esmon CT: Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982; 257:859-864
9. 9. Marlar RA, Kleiss AJ, Griffin JH: Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 1982; 59:1067-1072
10. 10. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, et al: The endothelial protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci U S A 1996; 93:10212-10216
11. 11. Moore KL, Andreoli SP, Esmon NL, et al: Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79:124-130
12. 12. Nawroth PP, Stern DM: Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745
13. 13. Conway EM, Rosenberg RD: Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8:5588-5592
14. 14. Nawroth PP, Handley DA, Esmon CT, et al: Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anti-coagulant activity. Proc Natl Acad Sci U S A 1986; 83:3460-3464
15. 15. Taylor FB Jr, Chang A, Esmon CT, et al: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboons. J Clin Invest 1987; 79:918-925
16. 16. Brandtzaeg P, Sandset PM, Joe GB, et al: Quantitative relation between plasma endotoxin, antithrombin, protein C, extrinsic coagulation pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 1989; 55:459-470
17. 17. Lorente JA, Garcia-Frade LJ, Landin L, et al: Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103:1536-1542
18. 18. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328:1323-1332
19. 19. Mesters RM, Mannucci PM, Coppola R, et al: Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996; 88:881-886
20. 20. Gruber A, Griffin JH: Direct detection of activated protein C in blood from human subjects. Blood 1992; 79:2340-2348
21. 21. Westfall PH, Young SS: Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment. New York, Wiley, 1993, p 44
22. 22. Haire WD, Ruby EI, Gordon BG, et al: Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA 1995; 274: 1289-1295
23. 23. Faioni EM, Krachmalnicoff A, Bearman SI, et al: Naturally occurring anticoagulants and bone marrow transplantation: Plasma protein C predicts the development of venocclusive disease of the liver. Blood 1993; 81: 3458-3462
24. 24. Hardaway RM: Trauma, sepsis and disseminated intravascular coagulation. J Intensive Care Med 1995; 10:145-152
25. 25. Esmon CT, Schwarz HP: An update on clinical and basic aspects of the protein C anti-coagulant pathway. Trends Cardiovasc Med 1995; 5:141-148
26. 26. Yan SB, Grinnell BW: Antithrombotic and anti-inflammatory agents of the protein C anticoagulant pathway. Ann Rep Med Chem 1994; 11:103-112
27. 27. Esmon CT, Ding W, Yasuhiro K, et al: The protein C pathway: New insights. Thromb Haemost 1997; 78:70-74
28. 28. Dreyfus M, Magny JF, Bridey F, et al: Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991; 325:1565-1568
29. 29. Dahlbäck B: Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923-927
30. 30. Ostermann H, Rothenburger M, Mesters RM, et al: Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy. Br J Haematol 1994; 88:332-337
31. 31. Marlar RA, Endres-Brooks J, Miller C: Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood 1985; 66:59-63
32. 32. Powars DR, Rogers ZR, Patch MJ, et al: Purpura fulminans in meningococcemia: Association with acquired deficiencies of protein C and S. N Engl J Med 1987; 317:571-572
33. 33. Hesselvik JF, Malm J, Dahlbäck B, et al: Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 1991; 65:126-129
34. 34. Leclerc F, Hazelzet J, Jude B, et al: Protein C and S deficiency in severe infectious purpura of children: A collaborative study of 40 cases. Intensive Care Med 1992; 18:202-205
35. 35. Roman J, Velasco F, Fernandez F, et al: Protein C, protein S and C4b-binding protein in neonatal severe infection and septic shock. J Perinat Med 1992; 20:111-116
36. 36. Powars D, Larsen R, Johnson J, et al: Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis 1993; 17:254-261
37. 37. Hazelzet JA, van der Voort E, Lindemans J, et al: Relation between cytokines and routine laboratory data in children with septic shock and purpura. Intensive Care Med 1994; 20: 371-374
38. 38. Fijnvandraat K, Derkx B, Peters M, et al: Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict a high mortality. Thromb Haemost 1995; 73:15-20
39. 39. Alcaraz A, Espana F, Sanchez-Cuenaca J, et al: Activation of the protein C pathway in acute sepsis. Thromb Res 1995; 79:83-93
40. 40. Epstein DJ, Bergum PW, Bajaj SP, et al: Radioimmunoassays for protein C and factor X: Plasma antigen levels in abnormal hemostatic states. Am J Clin Pathol 1984; 82: 573-581
41. 41. Marlar RA, Neumann A: Neonatal purpura fulminans due to homozygous protein C-or protein S deficiencies. Semin Thromb Haemost 1990; 16:299-309
42. 42. Ding W, Gu J-M, Fukudome K, et al: Upregulation of the message for rodent endothelial cell protein C receptor (EPCR) by endotoxin and thrombin. Abstr. Circulation 1996; 94:1-694
43. 43. Kurosawa S, Stearns-Kurosawa DJ, Carson CW, et al: Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: Lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 1998; 91:725-727
44. 44. Heeb MJ, Mosher D, Griffin JH: Activation and complexation of protein C and cleavage and decrease of protein S in plasma of patients with intravascular coagulation. Blood 1989; 73:455-461
45. 45. Espana F, Vicente V, Tabernero D, et al: Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intra-vascular coagulation and thrombotic disease. Thromb Res 1990; 59:593-608
46. 46. Hoogendoorn H, Nesheim ME, Giles AR: A qualitative and quantitative analysis of the activation and inactivation of protein C in vivo in a primate model. Blood 1990; 75: 2164-2171
47. 2-macroglobulin, in patients with disseminated intravascular coagulation. Thromb Haemost 1993; 69:448-453
48. 48. Moore KL, Esmon CT, Esmon NL: Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73:159-165
49. 49. Drake TA, Cheng J, Chang A, et al: Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 1993; 142: 1458-1470
50. 50. Bone RC, Fisher CJ, Clemmer TP, et al: Sepsis syndrome: A valid clinical entity. Crit Care Med 1989; 17:389-393
51. 51. Increase in national hospital discharge survey rates for septicemia - United States. 1979-1987. MMWR Morb Mortal Wkly Rep 1990; 39:31-34
52. 52. Salvo I, de Cian W, Musicco M, et al: The Italian sepsis study: Preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 1995; 21:S244-S249
53. 53. McCloskey RV, Straube RC, Sanders C, et al: Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS trial study group. Ann Intern Med 1994; 121:1-5
54. 54. Bone RC, Balk RA, Fein AM, et al: A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. The E5 sepsis study group. Crit Care Med 1996; 23:994-1006
55. 55. Fisher CJ, Dhainaut JA, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994; 271:1836-1843
56. 56. Natanson C, Hoffman WD, Suffredini AF, et al: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994; 120: 771-783
57. 57. Fisher CJ, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996; 334:1697-1702
58. 58. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-742
59. 59. Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997; 25:1095-1100
60. 60. Van der Poll T, Coyle SM, Levi M, et al: Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood 1997; 89:3727-3734
61. 61. Emerson TE, Fournel MA, Redens TB, et al: Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med 1989; 87(Suppl 3b):27-35
62. 62. Creasey AA, Chang ACK, Feigen L, et al: Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91:2850-2860
63. 63. Mesters RM, Flörke, Ostermann H, et al: Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 75: 902-907
64. 64. Grey T, Hau H, Salem HH, et al: Selective effects of protein C on activation of human monocytes by lipopolysaccharide, interferon-gamma, or PMA: Modulation of effects on CD11b and CD14 but not CD25 or CD54 induction. Transplant Proc 1993; 25: 2913-2914
65. 65. Grey ST, Hancock WW: A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein C by human mononuclear phagocytes. J Immunol 1996; 156: 2256-2263
66. 66. Taylor FB Jr, Chang A, Ferrell G, et al: C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991; 78: 357-363
67. 67. Murakami K, Okajima K, Uchiba M, et al: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Thromb Haemost 1996; 87:642-647
68. 68. Roback MG, Stack AM, Thompson C, et al: Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits. Shock 1998; 9:138-142
69. 69. Gerson WT, Dickerman JD, Bovill EG, et al: Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate. Pediatrics 1993; 91: 418-422
70. 70. Rivard GE, David M, Farrell C, et al: Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 1995; 126:646-652
71. 71. Rintala E, Seppala O, Kotilainen P, et al: Protein C in the treatment of coagulopathy in meningococcal disease. Lancet 1996; 347: 1767
72. 72. Smith OP, White B, Vaughan D, et al: Use of protein C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997; 350: 1590-1593
73. 73. Veldman A, Escuriola-Ettingshausen C, Beeg T, et al: Treatment of DIC in septic shock with protein C concentrate. Blood 1997; 90: 3271